Thymosin Alpha-1 Research Guide: Identity, Literature, Analysis and Documentation
Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.
Thymosin alpha-1 is a 28-residue peptide with an acetylated N-terminus, first isolated from calf thymus. Its sequence is unusual in two ways that matter in the laboratory: nearly a third of its residues are acidic, and it contains no aromatic amino acid at all. The synthetic form, thymalfasin, is an approved medicine in a number of countries, which is why its literature is largely clinical. This page collects the identity data, the research areas the literature covers, the analytical points, and the report on file for StarBio’s lot.
Identity
| Name | Thymosin alpha-1 (thymalfasin) |
|---|---|
| Type | Synthetic N-acetylated 28-residue peptide |
| CAS number | 62304-98-7 |
| Molecular weight | 3108.3 g/mol |
| Formula | C129H215N33O55 |
| Sequence | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Length | 28 (octacosapeptide) |
Origin and history
The peptide was isolated and sequenced in 1977 in the laboratory of Allan Goldstein, from a thymus preparation called thymosin fraction 5 that his group had been characterising since the 1960s. It was the first component of that mixture to be purified. Chemical synthesis followed, and the synthetic peptide was later developed as a medicine. The material StarBio supplies is a synthetic research chemical of the same sequence, sold for laboratory use only. It is not the medicine, and nothing on this page describes a use of it.
What the literature covers
The references on file for this compound span several research areas. They are listed here as areas of study, not as results.
- General reviews. A 2001 drug monograph [1], a 2016 review of immune modulation [3] and a comprehensive 2020 literature review [6].
- Clinical research by condition. Reviews and studies in chronic hepatitis B (2015) [4], sepsis (2018) [7], HIV-1 (2017) [9], cancer therapy (2023) [10] and severe acute pancreatitis (2025) [8].
- Recent immunology. A 2023 study of lymphocytes after SARS-CoV-2 infection [5] and a 2025 review on ageing [2].
- Measurement. A 2018 paper on serum levels of the natural peptide in health and disease [11].
These papers describe a pharmaceutical studied in patients. None describes research-grade material.
Analytical notes
Thymosin alpha-1 has no tryptophan, tyrosine or phenylalanine, so it has no absorbance at 280 nm at all. Purity has to be measured at 210 to 220 nm, where the peptide bonds absorb, and any method or concentration estimate that relies on 280 nm will simply not see it. It also contains no methionine and no cysteine, so it is resistant to oxidation.
With nine glutamate and aspartate residues against four lysines, the peptide is strongly acidic. It dissolves best at neutral to slightly alkaline pH and can be reluctant in acidic water, the opposite of most basic research peptides. Identity is confirmed by deconvolution to the 3108.3 average mass, and the N-terminal acetyl group accounts for 42 Da of that: material without it is a known synthesis impurity. Several aspartate residues are potential sites of slow isomerisation in solution.
Storage and stability
- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term
Documentation for StarBio lots
Every StarBio lot is analysed by an independent laboratory. The table lists the report on file for this compound.
| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested | |
|---|---|---|---|---|---|
| Thymosin Alpha-1 10 mg | Medutest WWB-TA10-3421 | 98.95% | 10 mg | Feb 6, 2026 | report |
Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.
References
- Thymosin alpha-1. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, PMID 11381492.
- Aging and Thymosin Alpha-1. International journal of molecular sciences, 2025, PMID 41373628.
- Immune Modulation with Thymosin Alpha 1 Treatment. Vitamins and hormones, 2016, PMID 27450734.
- Thymosin alpha-1 treatment in chronic hepatitis B. Expert opinion on biological therapy, 2015, PMID 25640173.
- Thymosin alpha 1 restores the immune homeostasis in lymphocytes during Post-Acute sequelae of SARS-CoV-2 infection. International immunopharmacology, 2023, PMID 36989892.
- Thymosin alpha 1: A comprehensive review of the literature. World journal of virology, 2020, PMID 33362999.
- Thymosin alpha 1 treatment for patients with sepsis. Expert opinion on biological therapy, 2018, PMID 30063866.
- Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. Frontiers in immunology, 2025, PMID 40599771.
- Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future microbiology, 2017, PMID 28106477.
- Thymosin α-1 in cancer therapy: Immunoregulation and potential applications. International immunopharmacology, 2023, PMID 36812669.
- Serum thymosin alpha 1 levels in normal and pathological conditions. Expert opinion on biological therapy, 2018, PMID 30063864.
Product page: Thymosin Alpha-1. Related guides: TB-500 research guide, Vip research guide, what 99% purity means, storing lyophilized peptides.
For laboratory research use only. Not for human or veterinary use.
Questions about Thymosin Alpha-1
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a n-acetylated 28-residue peptide (thymalfasin): 28 residues (octacosapeptide), molecular weight 3108.3 g/mol, CAS number 62304-98-7. It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.
Is Thymosin Alpha-1 the same as Thymalfasin?
Thymosin Alpha-1 is also listed as Thymalfasin. On a certificate or vial label, the CAS number (62304-98-7) and the sequence identify the material regardless of which name is used.
What are the CAS number, formula and molecular weight of Thymosin Alpha-1?
Thymosin Alpha-1 has CAS number 62304-98-7, molecular formula C129H215N33O55 and molecular weight 3108.3 g/mol. Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH. Identity of each StarBio batch is confirmed by mass spectrometry on the laboratory report.
Is StarBio's Thymosin Alpha-1 independently tested?
Yes. The current Thymosin Alpha-1 batch was tested by Medutest (Medutest report WWB-TA10-3421): 98.95% purity by HPLC, tested Feb 6, 2026. The report is on file in the COA library (report page).
How should Thymosin Alpha-1 be stored?
Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.
Where can I buy Thymosin Alpha-1 for laboratory research?
StarBio sells Thymosin Alpha-1 as 10 mg at $39.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.
New reports and guides, by email
A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.
For laboratory research use only. No dosing or protocol content is ever sent.

